Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Nov 01, 2017 9:32am

91 Views

Post# 26886889

RE:RE:RE:RE:RE:RE:RE:RE:Wallace still hard at work.

I know, mostly people don't realize manitoba is the center of canada not Toronto.
In fact I live in Eastern Canada but work in Western Canada.
Don't get me wrong, Im well aware that it is a hole.
Not much to offer, Winterpeg half the year. but ... sorry trying to find an upside, still thinking.

Bullboard Posts

Debt-free cannabis company set for next stage of growth